However, anti-CTLA-4 therapy’s potential in gynecological cancers is underexplored, and its modest monotherapy efficacy suggests combination strategies may better overcome immunosuppressive barriers [45]. The gene discussed is CTLA4; the disease is female reproductive organ cancer.